Efficacy of short-term low-dose benzbromarone versus low-dose febuxostat in the treatment of Chinese male gout patients with renal uric acid underexcretion and its influence on liver function
10.3760/cma.j.cn311282-20241011-00464
- VernacularTitle:小剂量非布司他及苯溴马隆治疗肾排泄减少型男性痛风患者的疗效及其对肝功能影响的短期研究
- Author:
Xin HUANG
1
;
Zhengdan WANG
;
Shuhui HU
;
Wenyan SUN
;
Rui ZHOU
;
Yingluo WANG
;
Tong YU
;
Yin CHEN
Author Information
1. 青岛大学附属医院内分泌与代谢疾病科，青岛 266003
- Publication Type:Journal Article
- Keywords:
Gout;
Uric acid typing;
Liver function abnormalities;
Uric acid-lowering therapy;
Febuxostat;
Benzbromarone;
Mixed-effects model
- From:
Chinese Journal of Endocrinology and Metabolism
2025;41(4):316-321
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the efficacy of low-dose febuxostat and low-dose benzbromarone in lowering serum uric acid and their impact on liver function in male patients with renal underexcretion gout.Methods:This prospective cohort study enrolled 303 patients with renal underexcretion gout and normal baseline liver function. Participants were assigned to either the low-dose febuxostat group(20 mg qd) or the low-dose benzbromarone group(25 mg qd). A linear mixed-effects model was used to compare the uric acid target achievement rate(<360 μmol/L) and changes in liver enzyme levels between the two groups.Results:At week 4, the proportion of patients achieving the serum uric acid target(<360 μmol/L) was significantly higher in the benzbromarone group than that in the febuxostat group(64.2% vs 42.3%, P<0.001), with a trend toward greater efficacy at weeks 8 and 12. The incidence of alanine aminotransferase(ALT) or aspartate aminotransferase(AST) elevation above the upper limit was significantly higher in the febuxostat group compared to the benzbromarone group(35.2% vs 13.85%, P<0.001). After adjusting for baseline liver enzyme levels in the mixed-effects model, mean ALT and AST levels remained significantly higher in the febuxostat group than those in the benzbromarone group at weeks 4, 8, and 12( P<0.05). In the febuxostat group, ALT and AST levels significantly increased over time during weeks 0-4 and 4-8 ( P<0.001), peaking at week 8 followed by a decreasing trend. By week 12, the levels were not significantly different from baseline ( P>0.05). Whereas there was no significant difference at each follow-up time point in the benzbromarone group( P>0.05). Conclusions:In male patients with renal underexcretion gout, low-dose benzbromarone demonstrated superior urate-lowering efficacy and better hepatic safety compared to low-dose febuxostat.
